Nachrichten zur Gilead Sciences Inc. Aktie

Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Gilead Sciences gears up for Q1 earnings with HIV drugs driving growth, but cell therapy headwinds and rising costs could…

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) closed at $130.84 in the latest trading session, marking a +1.55% move from the prior day.…

Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts

Gilead Sciences (GILD) reached $130.4 at the closing of the latest trading day, reflecting a -2.42% change compared to its…

Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?

BMY stands out vs GILD, supported by a cheaper valuation, strong growth portfolio, and improving earnings outlook despite generic headwinds.…

Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $135.87, denoting a -1.29% move from the…

Heres Why Gilead Sciences (GILD) Gained But Lagged the Market Today

In the most recent trading session, Gilead Sciences (GILD) closed at $140.45, indicating a +1.02% shift from the previous trading…

Gilead Sciences, Inc. (GILD) Discusses Proposed Acquisitions of Tubulis, Ouro and Arcellx and Strategic Pipeline Expansion Transcript

…

EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

· Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private Germany-based, clinical-stage biotechnology company ·…

Für bis zu 5 Milliarden Dollar! Gilead kauft Biotech-Firma aus München

Das Übernahme-Karussell im Biotech-Sektor dreht sich gefühlt von Woche zu Woche immer schneller. Erst am Ostermontag hat Neurocrine Biosciences die…

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the latest trading session, Gilead Sciences (GILD) closed at $139.37, marking a +2.22% move from the previous day.…

Gilead Sciences, Inc. (GILD) M&A Call Transcript

…

2 Defensive Dividends Growing Fast on AI Demand

Market Analysis by covering: Gilead Sciences Inc, Waste Management Inc. Read s Market Analysis on Investing.com…

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

Gilead Sciences (GILD) closed the most recent trading day at $134.25, moving 1.92% from the previous trading session.…

Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held…

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the…

ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T

By David Bautz, PhDNASDAQ: ESLAREAD THE FULL ESLA RESEARCH REPORTInitiating CoverageWe are initiating coverage of Estrella Immunopharma (NASDAQ: ESLA) with…

Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know

Gilead Sciences (GILD) reached $146.63 at the closing of the latest trading day, reflecting a +1.88% change compared to its…

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note

In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.…

Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript

…

Gilead pays $7.8bn to take full control of promising multiple myeloma therapy

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion,...…

Gilead Sciences Aktie: Neue HIV-Daten als Kurstreiber bis 2036

Zürich (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von UBS:Die Analysten von UBS stufen die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN:…

Gilead Sciences (GILD) is a Top-Ranked Momentum Stock: Should You Buy?

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Yescarta Label Expansion And Dividend Growth Shape Gilead Investment Case

FDA expands the label for Gilead Sciences CAR T-cell therapy Yescarta to include relapsed or refractory primary central nervous system…

Gilead Sciences Aktie: HIV-Story stützt Bewertung - Yeztugo stark, aber bereits eingepreist

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von BMO Capital Markets:Evan Seigerman, Analyst von BMO Capital Markets, stuft die Aktie von Gilead…

Gilead Sciences Aktie: Trotz Yeztugo-Dämpfer sieht Cantor 1 Mrd. USD Potenzial

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Cantor Fitzgerald:Die Analysten von Cantor Fitzgerald stufen die Aktie von Gilead Sciences Inc.…

Gilead Sciences Stock Spikes After Q4 Results: Time to Buy?

Biotech leader Gilead Sciences (GILD) made headlines on Wednesday, with its stock spiking nearly 6% after delivering favorable Q4 results…

Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of +1.91% and +4.63%, respectively, for the quarter ended December 2025. Do the…

Gilead quarterly results beat Wall Street estimates

Gilead Sciences on Tuesday reported fourth-quarter sales and profit that came in slightly above Wall Street estimates, while its 2026…

Gilead Sciences Aktie vor Q4 2025 Zahlen: 156 oder 103 USD? Analysten-Kursziele und Ratings

Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Is Gilead Sciences (GILD) a Buy Ahead of Its Upcoming Earnings Announcement?

The companys market-leading HIV franchise has fueled top-line growth.…

Gilead Sciences (GILD) Advances While Market Declines: Some Information for Investors

In the latest trading session, Gilead Sciences (GILD) closed at $141.95, marking a +1.72% move from the previous day.…

Why Gilead Sciences (GILD) Outpaced the Stock Market Today

Gilead Sciences (GILD) reached $131.14 at the closing of the latest trading day, reflecting a +1.57% change compared to its…

Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Gilead Sciences (GILD) closed at $122.59, indicating a +1.23% shift from the previous trading…

Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences…

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

Gilead Sciences (GILD) concluded the recent trading session at $118.3, signifying a -2.71% move from its prior days close.…

3 Cash-Flow Machines Investors May Want Heading Into 2026

Market Analysis by covering: Gilead Sciences Inc, Qualcomm Incorporated, Exxon Mobil Corp. Read s Market Analysis on Investing.com…

Why Gilead Sciences (GILD) Dipped More Than Broader Market Today

In the latest trading session, Gilead Sciences (GILD) closed at $123.18, marking a -1.38% move from the previous day.…

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug By Investing.com

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug…

Gilead Sciences (GILD) Increases Despite Market Slip: Heres What You Need to Know

Gilead Sciences (GILD) closed the most recent trading day at $121.36, moving +2.17% from the previous trading session.…

Heres Why Gilead Sciences (GILD) is a Strong Value Stock

Whether youre a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top…

Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.…

Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength

…

Gilead Sciences misses on revenue guidance estimates, shares drop 4% By Investing.com

Gilead Sciences misses on revenue guidance estimates, shares drop 4%…

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know

Gilead Sciences (GILD) concluded the recent trading session at $121.46, signifying a -2.11% move from its prior days close.…

Gilead Sciences Breaks Out To Record Highs, The Rally Has Room To Run

…

Gilead Sciences Aktie: Politik entscheidet, Q3 nur Nebengeräusch

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Cantor Fitzgerald:Cantor Fitzgerald habe das Kursziel für die Aktie von Gilead Sciences Inc.…

Gilead Sciences Aktie: Yeztugo-Start überzeugt Ärzte

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse der Citigroup:Geoff Meacham, Analyst der Citigroup, habe das Kursziel für die Aktie von Gilead…

Gilead Sciences reaches settlement on Biktarvy patent litigation with generics By Investing.com

Gilead Sciences reaches settlement on Biktarvy patent litigation with generics…